What Is Abbott Worth Right Now
Abbott Laboratories market capitalization stands at roughly 200 billion dollars as of mid 2025, making it one of the largest medical devices and health care companies by value on the public markets. The stock price reflects steady demand for its diagnostics, medical devices, nutrition, and pharmaceutical products across global markets. Investors track Abbott closely because its diversified business model spans several high growth health care segments. You can review its latest market data on the Yahoo Finance Abbott page. The company ranks among the top health care firms by market cap, competing with other large medical technology and diversified health care peers.
Market capitalization is calculated by multiplying the current share price by the total number of outstanding shares, and this figure changes every trading day based on investor sentiment and financial results. Abbott trades on the New York Stock Exchange under the ticker symbol ABT, and its share price movements directly affect its reported net worth on public markets. The company has a long history of dividend payments and share buybacks, which influence total shareholder return over time. Analysts use market cap, enterprise value, and price to earnings ratios to compare Abbott with other large cap health care and medical device companies.
Abbott Revenue, Earnings, and Business Segments
Abbott reported total annual revenue of roughly 30 billion dollars for its most recent full fiscal year, driven by strong sales in medical devices, diagnostics, nutrition, and pharmaceuticals. Its Medical Devices segment includes leading products in diabetes care, heart monitoring, and surgical equipment, while Diagnostics provides rapid tests and laboratory systems used in hospitals worldwide. Nutrition remains a core business through brands like Similac and Ensure, and the Pharmaceuticals segment focuses on hospital and specialty medicines. Detailed segment results and guidance are available in the latest Abbott earnings release.
In the most recent quarterly report, Abbott posted revenue growth driven by continued demand for its core medical devices and diagnostics, with adjusted earnings per share reflecting disciplined cost management. The company invests heavily in research and development to launch new products in areas such as continuous glucose monitoring and next generation diagnostic platforms. Revenue is reported in U.S. dollars, and international sales make up a large share of total revenue because Abbott operates in more than 160 countries. You can explore the full financial statements on the Abbott Investor Relations website.
Abbott Net Worth, Assets, and Financial Position
Balance Sheet and Total Assets
Abbott carries substantial total assets on its balance sheet, including cash, receivables, inventory, and long term investments in manufacturing and technology. The company funds its operations through a mix of equity, long term debt, and operating cash flow, and its credit ratings reflect a solid but leveraged financial profile. Investors examine the balance sheet to understand liquidity, debt levels, and the company's ability to fund future growth and dividends.
Cash Flow and Shareholder Returns
Abbott generates strong operating cash flow, which supports capital expenditures, acquisitions, and consistent shareholder returns through dividends and buybacks. The company has a history of raising its dividend annually and repurchasing billions of dollars in shares over the past decade. Free cash flow remains a key metric for evaluating Abbott's financial flexibility and its capacity to invest in new product development. You can follow the latest cash flow and capital allocation updates on the Abbott Investor Relations page.